Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Targets |
ERK1/2
|
---|---|
ln Vitro |
AG126 (10 μM; overnight) increases the ARPE-19 cells' viability[2].
AG126 at concentrations greater than 10 μM , they become toxic to ARPE-19 cells and can increase the toxicity of H2O2[2]. AG126 (0.1-100 μM) blocks the growth of BRMECs that is induced by VEGF[4] |
ln Vivo |
AG 126 (intraperitoneal injection; 1-10 mg/kg; 1 h and 6 h after Zymosan treatment) treatment decreases the severity of multiple organ failure (MOF) brought on by Zymosan-induced peritonitis in rats[3].
|
Animal Protocol |
Male Sprague-Dawley rats treated with Zymosan (500 mg/kg)[3]
10 mg/kg, 3 mg/kg or 1 mg/kg Intraperitoneal injection; 10, 3, or 1 mg/kg; 1 h and 6 h after Zymosan treatment |
References |
|
Additional Infomation |
2-[(3-hydroxy-4-nitrophenyl)methylidene]propanedinitrile is a nitrophenol.
Tyrphostin AG 126 is a member of the tyrphostin family of tyrosine kinase inhibitors, that actively blocks lipopolysaccharide-induced production of tumor necrosis factor-a and nitric oxide in macrophages. (NCI) |
Molecular Formula |
C₁₀H₅N₃O₃
|
---|---|
Molecular Weight |
215.17
|
Exact Mass |
215.033
|
Elemental Analysis |
C, 55.82; H, 2.34; N, 19.53; O, 22.31
|
CAS # |
118409-62-4
|
Related CAS # |
118409-62-4
|
PubChem CID |
2046
|
Appearance |
Light yellow to yellow solid powder
|
Density |
1.5±0.1 g/cm3
|
Boiling Point |
381.9±42.0 °C at 760 mmHg
|
Melting Point |
184 °C
|
Flash Point |
184.8±27.9 °C
|
Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
Index of Refraction |
1.689
|
LogP |
1.66
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
5
|
Rotatable Bond Count |
1
|
Heavy Atom Count |
16
|
Complexity |
388
|
Defined Atom Stereocenter Count |
0
|
SMILES |
N#C/C(C#N)=C/C1=CC=C([N+]([O-])=O)C(O)=C1
|
InChi Key |
DUQADSPERJRQBW-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C10H5N3O3/c11-5-8(6-12)3-7-1-2-9(13(15)16)10(14)4-7/h1-4,14H
|
Chemical Name |
2-[(3-hydroxy-4-nitrophenyl)methylidene]propanedinitrile
|
Synonyms |
AG 126; AG126; AG-126; UNII-7YA4AMD1JC; Tyrphostin A 10; Tyrphostin AG 126; Tyrphostin A 10; alpha-Cyano-(3-hydroxy-4-nitro)cinnamonitrile
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 43~100 mg/mL (199.9~464.8 mM)
Ethanol: ~2 mg/mL (~9.3 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.6475 mL | 23.2374 mL | 46.4749 mL | |
5 mM | 0.9295 mL | 4.6475 mL | 9.2950 mL | |
10 mM | 0.4647 mL | 2.3237 mL | 4.6475 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Saving of RPE cells by AG126 and 15d-PGJ2. ARPE-19 cells were treated with 10 μM AG126, 1 μM 15d-PGJ2 or a combination of these two agents overnight, followed by 1.4 mM H2O2 for 1 day (without testing agents), then processed for the MTT viability assay. BMC Ophthalmol . 2003 Mar 21:3:5. td> |
Effect of tyrphostin AG126 on nitrotyrosine formation and PARP activation. Am J Pathol . 2000 Jul;157(1):145-58. td> |
Effect of tyrphostin AG126 on myeloperoxidase activity and malondialdehyde levels in the lung. Am J Pathol . 2000 Jul;157(1):145-58. td> |
Effect of tyrphostin AG126 on lung injury. Am J Pathol . 2000 Jul;157(1):145-58. td> |
Effect of tyrphostin AG126 on the onset, the secondary lesion and on body weight gain in collagen-induced arthritis. Am J Pathol . 2000 Jul;157(1):145-58. td> |
Effect of tyrphostin AG126 treatment on histological damage score (A) and radiograph score (B). Am J Pathol . 2000 Jul;157(1):145-58. td> |
Effect of tyrphostin AG126 on malondialdehyde levels in the plasma: Malondialdehyde (MDA) levels in the plasma of CII-immunized rats killed at 35 days Am J Pathol . 2000 Jul;157(1):145-58. td> |